ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
The pivotal role and intervention strategies of BMAL1 mediated circadian clock dysregulation in intervertebral disc degeneration.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Melatonin rhythm-mimicking smart hydrogel for circadian clock regulation and promotion of intervertebral disc regeneration.Materials today. Bio · 2026Article
- Mechanotransduction in intervertebral disc degeneration: from compartment-specific sensors to translational frontiers.Frontiers in bioengineering and biotechnology · 2026Review
- Resveratrol Alleviates Intervertebral Disc Degeneration by Targeting NCOA4-Mediated Ferritinophagy Through Dual Antioxidant and Anti-Inflammatory Effects.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundIntervertebral disc degeneration (IVDD), a primary cause of chronic low back pain, involves extracellular matrix (ECM) degradation and nucleus pulposus cell apoptosis. While traditionally linked to mechanical stress, inflammation, oxidative stress, and metabolic dysfunction, emerging evidence positions circadian clock disruption as the central hub integrating these factors. Under physiological conditions, the core clock genes BMAL1/CLOCK regulate ECM homeostasis.
resultsIn IVDD, however, this rhythm is disrupted: abnormal mechanical stress inhibits BMAL1 via the RhoA/ROCK pathway; inflammation (e.g., IL-1β) suppresses BMAL1 transcription through NF-κB, creating a vicious cycle; aging-related oxidative stress and ferroptosis are exacerbated by BMAL1 epigenetic silencing; and metabolic disorders promote NLRP3 inflammasome activation via mTORC1-mediated autophagy suppression and miR-155-dependent BMAL1 mRNA decay. Consequently, circadian dysregulation accelerates ECM breakdown and mitochondrial apoptosis. This synthesis establishes a novel 'circadian-centric' model of IVDD, unifying multifactorial pathogenesis under the framework of rhythm disruption. It reveals precise pathways such as RhoA/BMAL1/ECM, bridging key mechanistic gaps. Therapeutically, this model advocates a paradigm shift from symptomatic management to circadian rhythm reconstruction. Potential strategies include restoring BMAL1 rhythmicity to reverse ECM catabolism, targeting the circadian-inflammatory axis (e.g., melatonin, IL-1β antagonists) to concurrently mitigate inflammation and oxidative damage, and employing chrono-therapeutic interventions such as timed mechanical loading or nighttime drug administration.
conclusionThis review provides a foundational rationale for developing chrono-precise diagnostics and treatments, aiming to redefine IVDD management toward endogenous rhythm restoration.
Indexed as
Identifiers
41498810What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.